(0.14%) 5 162.00 points
(0.11%) 38 875 points
(0.10%) 18 019 points
(1.04%) $78.92
(-0.09%) $2.14
(0.88%) $2 328.90
(2.54%) $27.37
(0.66%) $971.70
(-0.05%) $0.928
(-0.27%) $10.84
(-0.22%) $0.795
(0.04%) $91.49
-0.82% $ 1.210
Live Chart Being Loaded With Signals
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19...
Stats | |
---|---|
Dzisiejszy wolumen | 73 397.00 |
Średni wolumen | 460 746 |
Kapitalizacja rynkowa | 5.92M |
EPS | $0 ( 2024-03-29 ) |
Następna data zysków | ( $-0.540 ) 2024-05-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.530 |
ATR14 | $0.00600 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Springer Graig | Buy | 100 000 | Options |
2024-01-05 | Springer Graig | Buy | 25 000 | Options |
2024-01-05 | Sarnoff David | Buy | 25 000 | Options |
2024-01-05 | Pavell Jeff | Buy | 25 000 | Options |
2024-01-05 | Linsley Wayne | Buy | 25 000 | Options |
INSIDER POWER |
---|
100.00 |
Last 63 transactions |
Buy: 4 493 741 | Sell: 2 121 250 |
Wolumen Korelacja
Hoth Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
APOP | 0.925 |
CMLF | 0.887 |
RMRM | 0.88 |
EMBCV | 0.864 |
FEYE | 0.843 |
TDAC | 0.835 |
MAGS | 0.828 |
SVOK | 0.814 |
GAINL | 0.811 |
ISNS | 0.808 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hoth Therapeutics Inc Korelacja - Waluta/Towar
Hoth Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-66 834.00 (0.00 %) |
EPS: | $-9.75 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-28.95 |
Financial Reports:
No articles found.
Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej